Multiple targets in one drug: Zealand partners with Generate to develop AI-designed metabolic therapies
The collaboration will begin with two multispecific protein programs, exploring new treatment approaches for obesity and other metabolic diseases. Nearly $1.2 billion in potential milestone payments indicates the scale of the commitment, but these designs have yet to produce clinical efficacy results.